Introduction: Imaging with [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-JR11, and [18F]AlF-NOTA-JR11 was performed to analyze differences among the three probes and to analyze the correlation between the image and pathology parameters. Method: Tumor-bearing mice with different positive rates of somatostatin receptor II (SSTR2) were established with HEK293-SSTR2 and HEK293 cells, and imaging was performed on the same mouse with [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-JR11, and [18F]AlF-NOTA-JR11 at 20, 60, and 120 min. The image parameters were obtained, including the maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), standard deviation of SUVmean, tumor volume, and coefficient of variation (CoV). Immunohistochemistry (IHC) of the tumor was performed after imaging to obtain positive rate of SSTR2. Statistical analysis was performed to analyze the differences among the three imaging techniques and the correlations between the relative imaging parameter and IHC. Result: The SUVmax of [18F]AlF-NOTA-JR11 at 20 min and 60 min was higher than that of [68Ga]Ga-DOTA-TATE (p = 0.0015, 0.0035) and [68Ga]Ga-DOTA-JR11 (p = 0.033, 0.019), and no significant difference was found in the other groups (p > 0.05). There was a significant positive correlation between the positive rate and SUVmean of tumors with three tracers (p < 0.05). However, a significant negative correlation between the positive rate and CoV was found only in the [68Ga]Ga-DOTA-TATE group at 60 min and 120 min (p = 0.048, 0.026). Conclusion: [18F]AlF-NOTA-JR11 is more suitable for SSTR imaging within an hour than other two tracers. SUVmean of whole tumor can become an indicator for evaluating the positive rate of IHC, and the higher SUVmean of three tracers means a higher positive rate. However, the CoV is not applicable to the two antagonist tracers for evaluating the positive rate.

1.
Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139(3):742–53, 753.e1.
2.
Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, et al. Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy. Front Endocrinol. 2021;12:679000.
3.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw. 2018;16(6):693–702.
4.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.
5.
Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45(10):1386–93.
6.
Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, et al. Safety and efficacy of (68)Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57(5):708–14.
7.
Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30(10):1338–47.
8.
Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52(7):1110–8.
9.
Krebs S, O’Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK, et al. Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020;47(13):3047–57.
10.
Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [(18)F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [(68)Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129–40.
11.
Wieder H, Beer AJ, Poethko T, Meisetschlaeger G, Wester HJ, Rummeny E, et al. PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. Eur J Nucl Med Mol Imaging. 2008;35(2):264–71.
12.
Fonti R, Panico M, Pellegrino S, Pulcrano A, Vastarella LA, Torbati AHM, et al. Heterogeneity of SSTR2 expression assessed by (68)Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors. J Nucl Med. 2022;63(10):1509–14.
13.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.
14.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.
15.
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.
16.
Klomp MJ, Dalm SU, de Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord. 2021;22(3):495–510.
17.
Taelman VF, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu CI, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57(11):1805–10.
18.
Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, et al. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res. 2020;26(12):2946–55.
19.
Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022;49(5):1613–22.
20.
Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50(6):936–41.
21.
Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47(3):502–11.
22.
D’Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous (18)F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22(9):1793–803.
You do not currently have access to this content.